SECURITIES AND EXCHANGE COMMISSION
                             Washington, D.C. 20549

                                  SCHEDULE 13D

                   Under the Securities Exchange Act of 1934
                               (Amendment No. 3)*

                                Biogen Idec Inc.
                                (Name of Issuer)

                        Common Stock, Par Value $0.0005
                         (Title of Class of Securities)

                                   09062X103
                                 (CUSIP Number)

                               Marc Weitzen, Esq.
                                Icahn Capital LP
                          767 Fifth Avenue, 47th Floor
                            New York, New York 10153
                                 (212) 702-4388
                 (Name, Address and Telephone Number of Person
               Authorized to Receive Notices and Communications)

                                 March 20, 2010
            (Date of Event which Requires Filing of this Statement)

If  the filing person has previously filed a statement on Schedule 13G to report
the  acquisition  that  is  the subject of this Schedule 13D, and is filing this
schedule  because  of  Section 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check
the  following  box  /  /.

NOTE:  Schedules  filed in paper format shall include a signed original and five
copies of the schedule, including all exhibits. See Rule 13d-7 for other parties
to  whom  copies  are  to  be  sent.

*The  remainder  of this cover page shall be filled out for a reporting person's
initial filing on this form with respect to the subject class of securities, and
for  any  subsequent  amendment  containing  information  which  would  alter
disclosures  provided  in  a  prior  cover  page.

The information required on the remainder of this cover page shall not be deemed
to  be  "filed"  for the purpose of Section 18 of the Securities Exchange Act of
1934  ("Act") or otherwise subject to the liabilities of that section of the Act
but  shall  be  subject  to  all  other  provisions of the Act (however, see the
Notes).



                                  SCHEDULE 13D

Item 1. Security and Issuer

     The  Schedule  13D,  filed  with  the Securities and Exchange Commission on
August  11,  2008 by the Reporting Persons, as amended by Amendment No. 1, filed
on February 6, 2009 and Amendment No. 2 filed on January 28, 2010 (the "Schedule
13D")  with  respect  to  the  shares  of  Common  Stock, par value $0.0005 (the
"Shares"),  issued  by  Biogen  Idec  Inc.  (the  "Issuer") is hereby amended to
furnish  the  additional  information  set  forth  herein. All capitalized terms
contained  herein  but not otherwise defined shall have the meanings ascribed to
such  terms  in  the  Schedule  13D.

Item 4. Purpose of Transaction

     Item  4  of  the  Schedule  13D  is  hereby  amended by the addition of the
following:

     The  Issuer and Reporting Persons entered into an agreement dated March 20,
2010  (the  "Agreement"),  a  copy  of which is attached hereto as Exhibit I and
incorporated  herein  by  reference.

     The  Issuer  announced  on March 22, 2010 that it had appointed Dr. Eric K.
Rowinsky  and Dr. Stephen A. Sherwin to its Board of Directors and would include
Dr.  Eric  K.  Rowinsky  and Dr. Stephen A. Sherwin on its slate of nominees for
director  at  the 2010 Annual Meeting. The Reporting Persons agreed, among other
things,  that  they  would  vote  their  Shares  at that meeting for Dr. Eric K.
Rowinsky  and  Dr.  Stephen  A.  Sherwin  and up to two additional persons being
nominated  by  the Issuer, and would not otherwise solicit proxies in connection
with  the  2010  Annual  Meeting.

     The  Reporting  Persons  agreed  to  withdraw its letter, dated January 27,
2010,  that  provided  notice  to  the  Company  of  the  nomination  of certain
individuals  and  certain  proposed  business in connection with the 2010 Annual
Meeting.

     In  connection  with  the agreement, Mr. Icahn stated that "I am pleased we
were  able  to  reach  an agreement that is in stockholders' best interests. The
nominees  who will replace Messrs. Mullen and Ross are extremely qualified and I
believe  will  add  great value to Biogen. We look forward to continuing to work
together  constructively  to  drive performance and increase shareholder value."

Item 7. Materials to Be Filed as Exhibits.

     Item  7  is  hereby  amended  by  the  addition  of  the  following:

     Exhibit 1.     Settlement Agreement, dated March 20, 2010, among the Issuer
                    and the Reporting Persons.





                                   SIGNATURE

     After  reasonable  inquiry  and  to  the  best  of  each of the undersigned
knowledge and belief, each of the undersigned certifies that the information set
forth  in  this  statement  is  true,  complete  and  correct.

Dated:  March  22,  2010


HOPPER  INVESTMENTS  LLC
BARBERRY  CORP.
ICAHN  PARTNERS  MASTER  FUND  LP
ICAHN  PARTNERS  MASTER  FUND  II  LP
ICAHN  PARTNERS  MASTER  FUND  III  LP
ICAHN  OFFSHORE  LP
ICAHN  PARTNERS  LP
ICAHN  ONSHORE  LP
BECKTON  CORP.


HIGH  RIVER  LIMITED  PARTNERSHIP
     By:  Hopper  Investments  LLC,  general  partner


     By:  /s/ Edward E. Mattner
              --------------------
              Name:  Edward  Mattner
              Title:  Authorized  Signatory

ICAHN  CAPITAL  LP
     By:  IPH  GP  LLC,  its  general  partner
     By:  Icahn  Enterprises  Holdings  L.P.,  its  sole  member
     By:  Icahn  Enterprises  G.P.  Inc.,  its  general  partner

     By:  /s/ Dominick Ragone
          -------------------
          Name:  Dominick  Ragone
          Title:  Chief  Financial  Officer

IPH  GP  LLC
     By:  Icahn  Enterprises  Holdings  L.P.,  its  sole  member
     By:  Icahn  Enterprises  G.P.  Inc.,  its  general  partner

     By:  /s/ Dominick Ragone
          -------------------
          Name:  Dominick  Ragone
          Title:  Chief  Financial  Officer


ICAHN  ENTERPRISES  HOLDINGS  L.P.
     By:  Icahn  Enterprises  G.P.  Inc.,  its  general  partner

     By:  /s/ Dominick Ragone
          -------------------
          Name:  Dominick  Ragone
          Title:  Chief  Financial  Officer

ICAHN  ENTERPRISES  G.P.  INC.

By:  /s/ Dominick Ragone
     -------------------
     Name:  Dominick  Ragone
     Title:  Chief  Financial  Officer




/s/  Carl  C.  Icahn
--------------------
CARL  C.  ICAHN






      [Signature Page of Schedule 13D, Amendment No. 3 - Biogen Idec Inc.]



                                                                       EXHIBIT I



                                                                  EXECUTION COPY


                                   AGREEMENT
                                   ---------

     This Agreement dated March 20, 2010 (this "Agreement"), is by and among the
persons  and entities listed on Schedule A (collectively, the "Icahn Group", and
individually  a  "member" of the Icahn Group) and Biogen Idec Inc. (on behalf of
itself  and  its  Board  of  Directors,  as  defined herein) (the "Company"). In
consideration of and reliance upon the mutual covenants and agreements contained
herein,  and  for  other  good  and  valuable  consideration,  the  receipt  and
sufficiency  of  which  is  hereby  acknowledged,  the  parties  hereto agree as
follows:

     1. Board Appointment and Nomination.

          (a) The Company agrees:

               (i)  to  appoint  Eric  Rowinsky and Stephen A. Sherwin (the "New
          Class  1 Directors") as Class 1 directors of Board of Directors of the
          Company (the "Board of Directors"), in each case as soon as reasonably
          practicable  but  in  any  event  no  later  than  March  31,  2010;

               (ii)  to  include  the  New  Class  1  Directors  in its slate of
          nominees  for  election as Class 1 directors of the Board of Directors
          at the Company's 2010 annual meeting of stockholders (the "2010 Annual
          Meeting");  and

               (iii)  to  use  commercially  reasonable  efforts  to  cause  the
          election  of  the  New  Class  1  Directors at the 2010 Annual Meeting
          (including  recommending that the Company's stockholders vote in favor
          of  the election of the New Class 1 Directors and otherwise supporting
          them  for election in a manner no less rigorous and favorable than the
          manner  in  which  the  Company  supports  its  other  nominees in the
          aggregate).

          (b)  Effective  upon  the  public  announcement of the appointment, no
     later  than  March  31,  2010, of the New Class I Directors to the Board of
     Directors  as  provided  in Section 1(a)(i) of this agreement together with
     the  public  announcement  of  the  matters  in  Section  1(a)(ii)  of this
     Agreement, the Icahn Group's letter dated January 27, 2010 providing notice
     to  the  Company  of  the  nomination  of  certain  individuals and certain
     proposed business in connection with the 2010 Annual Meeting shall, without
     further  action  on  the  part  of  the Icahn Group, be withdrawn and of no
     further  force  and  effect.

     2. Proxy Contest and Other Matters; Press Release.

          (a)  From  and after the date hereof and provided that the Company has
     complied  and  is  complying with its obligations set forth in Section 1 of
     this Agreement, no member of the Icahn Group shall, directly or indirectly,
     and  each member of the Icahn Group shall cause each Affiliate or Associate
     (as  such  terms  are  hereinafter  defined)  of  any  such  members  (such
     Affiliates  and  Associates,  collectively  and  individually,  the  "Icahn
     Affiliates") not to, directly or indirectly, (i) become a "participant" (as
     such term is defined in Instruction 3 to Item 4 of Schedule 14A promulgated
     under  the  Exchange  Act)  in  or  actively  assist any third party in any
     "solicitation"  of any proxy, consent or other authority to vote any shares
     of  Common Stock (as such terms are defined under the Exchange Act) for use
     at  any time prior to or at the 2010 Annual Meeting, (ii) encourage, advise
     or  influence any other person or assist any third party in so encouraging,
     assisting  or  influencing  any  person  with  respect  to  the  giving  or
     withholding  of  any  proxy, consent or other authority to vote at any time
     prior  to  or  at  the  2010 Annual Meeting, (iii) present any proposal for
     consideration  for  action  by  stockholders at any time prior to or at the
     2010  Annual  Meeting,  (iv) grant any proxy, consent or other authority to
     vote with respect to any matters at any time prior to or at the 2010 Annual
     Meeting  (other  than  to the named proxies included in the Company's proxy
     card  for  the  2010  Annual  Meeting,  which shall include the New Class 1
     Directors and no more than two other nominees) or deposit any of the Common
     Stock  held by the Icahn Group or the Icahn Affiliates in a voting trust or
     subject  them  to a voting agreement or other arrangement of similar effect
     with  respect  to  the  2010  Annual  Meeting or (v) make any request under
     Section  220  of  the Delaware General Corporation Law at any time prior to
     the  2010  Annual  Meeting.  For  purposes  of  this  Agreement:  the terms
     "Affiliate" and "Associate" shall have the respective meanings set forth in
     Rule  12b-2  promulgated  by  the SEC under the Exchange Act, provided that
     neither  the  term  Affiliate  nor the term Associate shall include (i) any
     person  that  is  a  publicly held company and is otherwise an Affiliate or
     Associate by reason of the fact that a principal of any member of the Icahn
     Group  serves  as  a  member of the board of directors or similar governing
     body  of  such  company  or  (ii)  such member of the board of directors or
     similar  governing body of such publicly held company, to the extent acting
     solely  in  his  or  her  capacity  as such or (iii) any entity which is an
     Associate  solely by reason of clause (1) of the definition of Associate in
     such Rule 12b-2. As used in this Agreement, the terms "person" or "persons"
     shall  mean any individual, corporation (including not-for-profit), general
     or  limited  partnership, limited liability or unlimited liability company,
     joint  venture, estate, trust, association, organization or other entity of
     any  kind  or  nature.

          (b)  So  long  as  the  Company has complied and is complying with its
     obligations  set  forth  in Section 1 of this Agreement, each member of the
     Icahn  Group  shall  cause  all  shares of Common Stock owned of record and
     shall  instruct  the  record  owner,  in case of all shares of Common Stock
     beneficially  owned  (as defined in Rule 13d-3 promulgated by the SEC under
     the  Exchange  Act) but not owned of record, directly or indirectly, by it,
     or  by  any  Icahn  Affiliate,  as  of  the record date for the 2010 Annual
     Meeting,  to  be  present  for quorum purposes and to be voted, at the 2010
     Annual Meeting or at any adjournments or postponements thereof, in favor of
     the  directors  nominated  by  the  Board  for  election at the 2010 Annual
     Meeting  which shall include the New Class 1 Directors and no more than two
     other  nominees.

          (c)  The Company and the Icahn Group shall announce this Agreement and
     the  material terms hereof by means of a press release in the form attached
     hereto  as  Exhibit  B  (the  "Press Release") as soon as practicable on or
     after  the  date  hereof.

          3.  Representations  and  Warranties.  Each  of  the  parties  hereto
     represents  and  warrants  to  the  other  party  that:

          (a)  such  party  has  all  requisite  company  authority and power to
     execute  and  deliver  this  Agreement  and  to consummate the transactions
     contemplated  hereby;

          (b)  the execution and delivery of this Agreement and the consummation
     of  the  transactions  contemplated  hereby  have  been  duly  and  validly
     authorized  by  all  required  company  or other action on the part of such
     party  and  no other proceedings on the part of such party are necessary to
     authorize the execution and delivery of this Agreement or to consummate the
     transactions  contemplated  hereby;

          (c) this Agreement has been duly and validly executed and delivered by
     such  party  and constitutes the valid and binding obligation of such party
     enforceable  against  such  party  in  accordance  with  its  terms;  and

          (d)  this  Agreement  will  not  result in a violation of any terms or
     provisions  of  any  agreements to which such person is a party or by which
     such party may otherwise be bound or of any law, rule, license, regulation,
     judgment,  order  or  decree  governing  or  affecting  such  party.

          4.  Miscellaneous.  The  parties  hereto  shall  be  entitled  to  an
     injunction  or  injunctions  to  prevent  breaches of this Agreement and to
     enforce specifically the terms and provisions of this Agreement exclusively
     in  the  Court of Chancery or other federal or state courts of the State of
     Delaware, in addition to any other remedy to which they are entitled at law
     or  in  equity.  Furthermore,  each  of  the parties hereto (a) consents to
     submit  itself  to  the  personal  jurisdiction of the Court of Chancery or
     other  federal  or  state  courts of the State of Delaware in the event any
     dispute  arises  out  of this Agreement or the transactions contemplated by
     this Agreement, (b) agrees that it shall not attempt to deny or defeat such
     personal  jurisdiction  by  motion or other request for leave from any such
     court,  (c)  agrees  that  it  shall  not bring any action relating to this
     Agreement  or  the transactions contemplated by this Agreement in any court
     other  than  the  Court of Chancery or other federal or state courts of the
     State  of Delaware, and each of the parties irrevocably waives the right to
     trial  by  jury,  (d)  agrees  to  waive  any bonding requirement under any
     applicable  law,  in the case any other party seeks to enforce the terms by
     way of equitable relief and (e) each of the parties irrevocably consents to
     service  of  process  by  a  reputable  overnight  mail  delivery  service,
     signature  requested,  to  the  address of such parties' principal place of
     business  or  as otherwise provided by applicable law. THIS AGREEMENT SHALL
     BE  GOVERNED  IN  ALL  RESPECTS,  INCLUDING  WITHOUT  LIMITATION  VALIDITY,
     INTERPRETATION  AND  EFFECT,  BY THE LAWS OF THE STATE OF DELAWARE, WITHOUT
     GIVING  EFFECT  TO  THE  CHOICE  OF LAW PRINCIPLES OF SUCH STATE THAT WOULD
     COMPEL  THE  APPLICATION  OF  THE  LAW  OF  ANOTHER  JURISDICTION.

          5.  Entire Agreement. This Agreement contains the entire understanding
     of the parties with respect to the subject matter hereof and may be amended
     only  by  an  agreement  in  writing  executed  by  the  parties  hereto.

          6.  Notices.  All notices, consents, requests, instructions, approvals
     and  other  communications  provided  for  herein  and all legal process in
     regard  hereto  shall be in writing and shall be deemed validly given, made
     or  served,  if (a) given by telecopy, when such telecopy is transmitted to
     the  telecopy  number  set  forth below and the appropriate confirmation is
     received  or (b) if given by any other means, when actually received during
     normal  business  hours  at  the  address  specified  in  this  subsection:

          if  to the Company:         Biogen Idec Inc.
                                      14 Cambridge Center
                                      Cambridge, MA  02142
                                      Attention:  General  Counsel
                                      Facsimile:  (617)  679-2617

          with a copy to:             Wachtell, Lipton, Rosen & Katz
                                      51 West 52nd Street
                                      New York, NY 10019
                                      Attention:  Patricia A. Vlahakis
                                      Facsimile: (212) 403-2000

          if to the Icahn Group:      Icahn Capital LP
                                      767 Fifth Avenue, 47th Floor
                                      New York, NY 10153
                                      Attention:  Marc Weitzen
                                      Facsimile:  (212) 688-1158

          7.  Severability.  If  at  any time subsequent to the date hereof, any
     provision  of  this  Agreement  shall  be  held  by  any court of competent
     jurisdiction  to be illegal, void or unenforceable, such provision shall be
     of  no  force  and  effect,  but the illegality or unenforceability of such
     provision  shall  have no effect upon the legality or enforceability of any
     other  provision  of  this  Agreement.

          8.  Counterparts.  This  Agreement  may  be  executed  in  two or more
     counterparts  (including  by  facsimile  or  PDF)  which  together  shall
     constitute  a  single  agreement.

          9.  Successors  and Assigns. This Agreement shall not be assignable by
     any  of the parties to this Agreement but shall be binding on successors of
     the  parties  hereto.

          10.  No  Third  Party  Beneficiaries. This Agreement is solely for the
     benefit  of the parties hereto and is not enforceable by any other persons.

          11.  Fees  and Expenses. Neither the Company, on the one hand, nor the
     Icahn  Group,  on  the  other  hand,  will  be  responsible for any fees or
     expenses  of  the  other  in  connection  with  this  Agreement.

          12.  Interpretation  and  Construction.  Each  of  the  parties hereto
     acknowledges  that  it  has  been  represented  by  counsel  of  its choice
     throughout  all  negotiations  that  have  preceded  the  execution of this
     Agreement,  and  that  it  has  executed  the  same with the advice of said
     independent counsel. Each party and its counsel cooperated and participated
     in  the  drafting  and  preparation  of  this  Agreement  and the documents
     referred to herein, and any and all drafts relating thereto exchanged among
     the  parties shall be deemed the work product of all of the parties and may
     not  be  construed  against  any  party  by  reason  of  its  drafting  or
     preparation.  Accordingly, any rule of law or any legal decision that would
     require  interpretation  of  any  ambiguities in this Agreement against any
     party  that  drafted  or  prepared  it  is  of no application and is hereby
     expressly  waived  by  each of the parties hereto, and any controversy over
     interpretations  of  this  Agreement  shall  be  decided without regards to
     events  of  drafting  or  preparation.

                            [Signature Pages Follow]




     IN WITNESS WHEREOF, each of the parties hereto has executed this Agreement,
or  caused  the  same to be executed by its duly authorized representative as of
the  date  first  above  written.

                          BIOGEN IDEC INC.


                          By:  ________________________________________
                               Name:
                               Title:

                          ICAHN PARTNERS MASTER FUND LP
                          ICAHN PARTNERS MASTER FUND II LP
                          ICAHN PARTNERS MASTER FUND III LP
                          ICAHN OFFSHORE LP
                          ICAHN PARTNERS LP
                          ICAHN ONSHORE LP
                          ICAHN CAPITAL LP
                          IPH GP LLC
                          ICAHN ENTERPRISES G.P. INC.
                          ICAHN ENTERPRISES HOLDINGS L.P.
                          BECKTON CORP.
                          HOPPER INVESTMENTS LLC
                          BARBERRY CORP.
                          HIGH RIVER LIMITED PARTNERSHIP
                            By: Hopper Investments LLC, general partner


                            By:  /s/ Edward E. Mattner
                                 ---------------------
                                 Name:  Edward E. Mattner
                                 Title:  Authorized Signatory


                          ICAHN CAPITAL LP
                            By: IPH GP LLC, its general partner
                            By: Icahn Enterprises Holdings L.P., its sole member
                            By: Icahn Enterprises G.P. Inc., its general partner
                          IPH GP LLC
                            By: Icahn Enterprises Holdings L.P., its sole member
                            By: Icahn Enterprises G.P. Inc., its general partner
                          ICAHN ENTERPRISES HOLDINGS L.P.
                            By: Icahn Enterprises G.P. Inc., its general partner
                          ICAHN ENTERPRISES G.P. INC.
                            By:  /s/ Dominick Ragone
                                 -------------------
                                 Name:  Dominick Ragone
                                 Title:  Chief Financial Officer

                          CARL C. ICAHN

                          /s/ Carl C. Icahn
                          -----------------





                                   SCHEDULE A
                                   ----------
                         High River Limited Partnership
                             Hopper Investments LLC
                                 Barberry Corp.
                         Icahn Partners Master Fund LP
                        Icahn Partners Master Fund II LP
                       Icahn Partners Master Fund III LP
                               Icahn Offshore LP
                               Icahn Partners LP
                                Ichan Onshore LP
                                Icahn Capital LP
                                   IPH GP LLC
                        Icahn Enterprises Holdings L.P.
                          Icahn Enterprises G.P. Inc.
                                 Beckton Corp.
                                 Carl C. Icahn


                                   EXHIBIT B
                                   ---------


                              [BIOGEN LETTERHEAD]




           BIOGEN IDEC APPOINTS ERIC ROWINSKY AND STEPHEN SHERWIN TO
          BOARD OF DIRECTORS PURSUANT TO AGREEMENT WITH ICAHN PARTNERS

                    ICAHN AGREES TO SUPPORT COMPANY NOMINEES

                             AT 2010 ANNUAL MEETING

CAMBRIDGE,  MASS.,  MARCH [], 2010 -- Biogen Idec (NASDAQ: BIIB) today announced
that  Dr. Eric K. Rowinsky and Dr. Stephen A. Sherwin have been appointed to its
Board  of  Directors  pursuant to an agreement with Icahn Partners. Dr. Rowinsky
was  proposed  as  a  nominee to the Board by Icahn Partners and Dr. Sherwin was
selected  by  the  Company  as  part  of  its process to identify new directors.

Under  the  terms of the agreement, Icahn Partners has agreed to vote its shares
at  the 2010 Annual Meeting for Biogen Idec's nominees, who will include current
directors  Nancy  L.  Leaming  and  Brian S. Posner as well as Drs. Rowinsky and
Sherwin.  In  addition,  under  the  terms of the agreement, Icahn Partners will
withdraw  its  notice of nomination of persons for election as directors and its
proposal  to  amend  Biogen Idec's Bylaws to limit the size of the Board. Biogen
Idec  has  temporarily increased the number of seats on the Board from 12 to 13.
James  C.  Mullen  and  Bruce  R. Ross will complete their current terms and, as
previously  announced, will not stand for reelection at the 2010 Annual Meeting.
Following  the  2010  Annual  Meeting,  there  will  be  12  seats on the Board.

William  D.  Young,  Chairman  of the Board of Directors, said, "We believe that
adding  Drs.  Sherwin  and  Rowinsky,  both  of  whom  bring relevant skills and
significant  industry  experience to the Board, is a positive outcome for Biogen
Idec  and  its  stockholders  and  we  look  forward  to  working  with  them."

Carl  Icahn, founder and CEO of Icahn Partners, said, "I am pleased we were able
to  reach an agreement that is in stockholders' best interests. The nominees who
will  replace Messrs. Mullen and Ross are extremely qualified and I believe will
add  great  value  to  Biogen.  We  look  forward to continuing to work together
constructively  to  drive  performance  and  increase  shareholder  value."

The  agreement between Biogen Idec and Icahn Partners LP will be filed in a Form
8-K with the Securities and Exchange Commission. The Company expects to file its
proxy  materials  for  the  2010  Annual  Meeting  in  the  near  future.

BIOGRAPHY OF DR. ERIC K. ROWINSKY

Dr.  Rowinsky,  53,  has served as a director at Adventrx Pharmaceuticals (AMEX:
ANX)  since  February  2008.  Dr.  Rowinsky  recently  served  as Executive Vice
President Clinical Development and Regulatory at ImClone Systems Incorporated, a
wholly-owned  subsidiary  of  Eli  Lilly  and  Company. Prior to joining ImClone
Systems  in  2005,  Dr.  Rowinsky  focused  his  academic efforts in cancer drug
development  as  the  Director  of  Clinical  Research and later Director of the
Institute  for Drug Development of the Cancer Therapy and Research Center in San
Antonio  and the SBC Endowed Chair for Early Drug Development from 1996 to 2005.
He  was  also Clinical Professor of Medicine in the Division of Medical Oncology
at  the  University  of  Texas Health Science Center at San Antonio from 1996 to
2006.  From  1987  to  1996,  Dr.  Rowinsky  served as an Associate Professor of
Oncology  at  the  Johns  Hopkins  University  School  of  Medicine.  He  was  a
longstanding  NCI  principal  investigator  on  U01  anticancer drug development
grants  and  integrally  involved  in  pivotal  clinical  and  preclinical
investigations which led to the development of paclitaxel, docetaxel, topotecan,
irinotecan, erlotinib and gefitinib, among others. Dr. Rowinsky's honors include
receipt  of  the career development award of the American Cancer Society and the
6th  Annual  Emil  J.  Freireich  Award  for  outstanding achievement of a young
researcher  in  clinical  cancer  therapeutics.

Dr. Rowinsky received his B.A. degree from New York University and his M.D. from
the  Vanderbilt  University  School  of  Medicine.  Following  his  residency in
internal  medicine  at  the  University  of  California, he completed fellowship
training in medical oncology at the Johns Hopkins University School of Medicine.

BIOGRAPHY OF DR. STEPHEN A. SHERWIN

Dr.  Sherwin,  61,  has  more  than  30 years of experience in senior leadership
positions  at  large  and  small  publicly  traded  biotechnology  companies. He
co-founded and is Chairman of Ceregene, Inc., a biotechnology company focused on
the  treatment  of  major  neurodegenerative disorders, and Abgenix, Inc., which
specialized  in  the discovery, development and manufacture of human therapeutic
antibodies  (Abgenix  was acquired by Amgen in 2006). He also served as Chairman
and  CEO of Cell Genesys until its acquisition by BioSante Pharmaceuticals, Inc.
(NASDAQ:  BPAX)  in  July  2009,  and  he  worked  at  Genentech for seven years
including  as  Vice  President  of  Clinical  Research. Dr. Sherwin is currently
Chairman  of  the  Biotechnology  Industry  Organization  and  is  a director of
BioSante,  Neurocrine  BioSciences  (NASDAQ:  NBIX)  and  Rigel  Pharmaceuticals
(NASDAQ:  RIGL).

Dr.  Sherwin received his B.A. in biology from Yale University and his M.D. from
Harvard  Medical  School. He is board certified in internal medicine and medical
oncology.

ABOUT BIOGEN IDEC

Biogen  Idec  creates new standards of care in therapeutic areas with high unmet
medical needs. Founded in 1978, Biogen Idec is a global leader in the discovery,
development,  manufacturing  and  commercialization  of  innovative  therapies.
Patients  worldwide benefit from Biogen Idec's significant products that address
diseases  such  as  lymphoma,  multiple  sclerosis and rheumatoid arthritis. For
product  labeling,  press releases and additional information about the company,
please  visit  www.biogenidec.com.

BIOGEN IDEC MEDIA CONTACT:
Amy Reilly, 617-914-6524
Associate Director, Public Affairs
or
BIOGEN IDEC INVESTOR RELATIONS CONTACT:
Eric Hoffman, 617-679-2812
Director, Investor Relations
                                   # # # # #